GlassScriptPhysician profile
Esmat M Mustafa
NPI 1033307574
$7,391.37
in general payments reported to CMS, 2019-2025
33 companies · $1,957 in 2025
The $1,957 reported for 2025 was more than what 89% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $674 · 2020: $347 · 2021: $511 · 2022: $940 · 2023: $1,409 · 2024: $1,554 · 2025: $1,957.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,841 · Education: $79.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,840.70 |
| Education | $79.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,832.16 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $876.78 | 2019-2025 | Jynarque, Voyxact |
| Mallinckrodt Hospital Products INC. | $627.80 | 2021-2025 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $627.72 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $444.38 | 2021-2024 | Xarelto |
| Amgen INC. | $409.42 | 2023-2025 | Krystexxa, Repatha |
| Travere Therapeutics, INC. | $328.63 | 2021-2024 | |
| Vifor Pharma, INC. | $303.56 | 2020-2022 | |
| Alnylam Pharmaceuticals INC. | $270.87 | 2023 | Givlaari, Amvuttra |
| Ani Pharmaceuticals, INC. | $251.61 | 2023-2025 | Purified Cortrophin Gel |
| Daiichi Sankyo INC. | $245.93 | 2022-2025 | Injectafer |
| Akebia Therapeutics INC | $113.26 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $98.58 | 2024-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $96.69 | 2025 | |
| Fresenius USA Marketing, INC. | $94.93 | 2021-2025 | Velphoro |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $84.64 | 2024-2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $77.77 | 2022-2024 | Tarpeyo |
| Alexion Pharmaceuticals, INC. | $74.85 | 2019-2024 | Ultomiris |
| Horizon Therapeutics Plc | $62.58 | 2019-2023 | Krystexxa |
| Genentech USA, INC. | $59.15 | 2019 | |
| Aurinia Pharma U.S., INC. | $53.67 | 2022 | |
| Astellas Pharma US INC | $51.11 | 2025 | Cresemba |
| Shield Therapeutics INC | $41.69 | 2025 | |
| Glaxosmithkline, LLC. | $40.61 | 2020-2024 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.31 | 2024 | Jardiance |
| Opko Pharmaceuticals, LLC | $39.53 | 2022 | |
| Novo Nordisk INC | $33.70 | 2019-2025 | Ozempic |
| Veloxis Pharmaceuticals, INC. | $26.06 | 2022 | |
| Boston Scientific Corporation | $24.60 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $16.18 | 2019 | |
| Genzyme Corporation | $16.02 | 2019 | |
| Medtronic, INC. | $15.51 | 2021 | |
| Lilly USA, LLC | $11.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Esmat Mustafa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.